Europe – Page 36 – pharmaceutical daily

December 15, 2021 Off

Sartorius and HOF Sonderanlagenbau Partnership Creates Streamlined Offering of Freeze-Thaw Solutions for Biological Products

Sartoriusand HOF Sonderanlagenbau, announced a partnership today to integrate two HOF horizontal plate freeze-thaw units into Sartorius’ portfolio offering customers a full suite of compatible freeze-thaw equipment and consumables. This partnership will enable faster and easier implementation of robust frozen drug substance management platforms through improved validation and purchase support from a single supplier.

December 13, 2021 Off

Dupixent significantly improved disease severity in a trial that met all endpoints

By Dino Mustafić

Positive Phase 3 results show adding Dupixent (dupilumab) to standard-of-care topical corticosteroids (TCS) significantly improved skin clearance and reduced overall disease severity and itch in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis.

December 13, 2021 Off

Acacia Pharma completes its post-approval requirement clinical trial testing Barhemsys in individuals with severe renal impairment

By Dino Mustafić

Acacia Pharma Group has completed its post-approval requirement clinical trial investigating the effects of BARHEMSYS® (amisulpride injection) in individuals with severe renal impairment.

December 13, 2021 Off

Study shows positive results for Roche’s Hemlibra in people with moderate or mild haemophilia A

By Dino Mustafić

Roche interim analysis of the phase III HAVEN 6 study, which show Hemlibra (emicizumab) demonstrated a favourable safety profile and effective bleed control in people with moderate or mild haemophilia A without factor VIII inhibitors.

December 13, 2021 Off

Roche launches system to advance sequencing technologies

By Dino Mustafić

Roche has launched the AVENIO Edge System, a core component of Roche’s strategy to advance sequencing technologies. Built on best-in-class foundational capabilities to deliver a fully-automated, integrated sequencing solution.

December 7, 2021 Off

Pure Tech kicks off study for its neuro conditions treatment candidate

By Dino Mustafić

PureTech Health has kicked off a clinical study of LYT-300 (oral allopregnanolone), its wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 is the third clinical-stage, wholly-owned candidate from PureTech’s pipeline.

December 7, 2021 Off

Bavarian Nordic A/S issues 6,373,680 New Ordinary Shares

By GlobeNewswire

Bavarian Nordic A/S (“Bavarian Nordic” or the “Company”) announced its intention to raise new capital through an accelerated bookbuilding process.…

October 11, 2021 Off

Sandoz completes acquisition of GSK’s cephalosporin business

By Dino Mustafić

Sandoz, a Novartis division, has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets,…

September 30, 2021 Off

Novartis data show rapid and effective disease activity control with remibrutinib in patients with chronic spontaneous urticaria

By Dino Mustafić

Novartis today announced positive Phase IIb data showing remibrutinib (LOU064), a potentially best-in-class oral BTK inhibitor, demonstrated rapid and effective disease control in patients with inadequately controlled chronic spontaneous urticaria (CSU).

September 30, 2021 Off

LEO Pharma shared new Adtralza results

By Dino Mustafić

LEO Pharma shared results showing that after two years of continuous treatment with Adtralza, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference